Jazz Pharmaceuticals plc JAZZ

Zymeworks Announces Participation in Upcoming Investor Conferences

GlobeNewswire Inc. · 70d ago

Pheochromocytoma and Paraganglioma Market to Exhibit Growth at 7.3% CAGR by 2036 Driven by the Advent of Drug Classes Such as SSTR2 analogs, Dopamine Receptor D2 Agonists, TAAs or TSAs, and Others | DelveInsight

GlobeNewswire Inc. · 93d ago

Artios Strengthens Leadership Team to Accelerate Late-Stage Development of Potential First-in-Class Oncology Pipeline

GlobeNewswire Inc. · 156d ago

Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

GlobeNewswire Inc. · 160d ago

Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed?

The Motley Fool · 176d ago

Jazz Pharmaceuticals' Drug Extends Survival Past Two Years in Advanced Stomach Cancer Trial

Benzinga · 196d ago

Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit

GlobeNewswire Inc. · 197d ago

Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans

Benzinga · 247d ago

Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz

Benzinga · 273d ago

FDA approves Roche’s Tecentriq plus lurbinectedin as first-line maintenance therapy for extensive-stage small cell lung cancer

GlobeNewswire Inc. · 292d ago

Ligand to Participate in September Investor Conferences

GlobeNewswire Inc. · 336d ago

Air Canada Suspends Plans to Restart Operations after CUPE Defies CIRB Directive to Return to Work

Benzinga · 339d ago

Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight

GlobeNewswire Inc. · 345d ago

Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation

GlobeNewswire Inc. · 387d ago

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

GlobeNewswire Inc. · 418d ago

Chimerix Reports Fourth Quarter and Year End 2024 Financial Results

GlobeNewswire Inc. · 488d ago

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

GlobeNewswire Inc. · 608d ago

VEON’s Jazz Launches FikrFree: An AI-Powered Digital Marketplace to Unlock Affordable Insurance and Healthcare in Pakistan

GlobeNewswire Inc. · 636d ago

Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker

The Motley Fool · 642d ago

Breast Cancer Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

GlobeNewswire Inc. · 659d ago

Jazz And Hikma Accused Of Delaying Sleep Disorder Generic Drug To Maintain High Prices

Benzinga · 693d ago

VEON’s Jazz Secures Pakistan’s Largest Long-Term Private Sector Syndicated Credit Facility of up to PKR 75 billion - GlobeNewswire

GlobeNewswire Inc. · 730d ago